Y. H. Chen
A5035548980- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Atherosclerosis and Cardiovascular Diseases
- Pharmacological Effects of Natural Compounds
- Erythrocyte Function and Pathophysiology
- Lymphoma Diagnosis and Treatment
- Lysosomal Storage Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Cytokine Signaling Pathways and Interactions
- Blood properties and coagulation
- Mosquito-borne diseases and control
- Toxoplasma gondii Research Studies
- Liver Diseases and Immunity
Taichung Veterans General Hospital
2022-2024
Soochow University
2024
Mutations in the gene encoding lysosomal enzyme glucocerebrosidase (GCase) are responsible for Gaucher disease (GD) and considered strongest genetic risk factor Parkinson’s (PD) Lewy body dementia (LBD). GCase deficiency leads to extensive accumulation of glucosylceramides (GCs) cells contributes neuropathology GD, PD, LBD by triggering chronic neuroinflammation. Here, we investigated mechanisms which GC induces We found that within microglia induced pharmacological inhibition triggered...
<h3>Background:</h3> The lupus low disease activity state (LLDAS) is a treat-to-target that has been prospectively validated as protective from organ damage, death, and loss of health-related quality life for patients with SLE. 2023 EULAR recommendations the management SLE advised glucocorticoid (GC) dose no more than 5mg/day [1] whereas GC threshold in definition LLDAS 7.5mg/day [2]. <h3>Objectives:</h3> We sought to determine if lowering ceiling 5 mg/day (LLDAS-5) was associated improved...
<h3>Background:</h3> In patients with systemic lupus erythematosus (SLE), treatment options are limited. Anti-malarials and immunosuppressive therapies widely used even though toxicity intolerance may limit persistence, or 'survival'. The predictors impact of drug survival anti-malarials in SLE unknown. <h3>Objectives:</h3> We sought to identify patient disease-related factors that associated anti-malarial (AM) immunosuppressant agents (IS) stable SLE. also analysed the on disease flares....
<h3>Background:</h3> A subset of patients with systemic lupus erythematosus (SLE) suffer serious manifestations and are relatively resistant to conventional treatments, such as combinations glucocorticoids (GC) immunosuppressive (IS) therapy. Clear definitions severe refractory SLE (srSLE) lacking, limiting its reporting in real-world data from observational cohorts or utility trial enrolment. <h3>Objectives:</h3> We sought evaluate a potential definition srSLE by describing clinical...
<h3>Background:</h3> While glucocorticoids and immunosuppressive therapies are key treatment approaches in SLE, these may contribute to damage accrual. Given the long horizon of tapering therapy stable SLE is often considered, but whether this approach impacts accrual unknown. <h3>Objectives:</h3> We aim compare time new among patients whose and/or were tapered after achieving target, versus those was continued on same doses. <h3>Methods:</h3> followed (ACR/SLICC criteria) from 13...
<h3>Background:</h3> There has been a long-standing interest in the use of biomarkers SLE, both to measure current disease activity and predict outcomes. Erythrocyte sedimentation rate (ESR), non-specific biomarker inflammation, shown correlate with SLE as well flares organ damage some studies, yet it is not used clinical trial endpoints. <h3>Objectives:</h3> We sought evaluate associations ESR flares, mortality large, multi-national cohort patients. <h3>Methods:</h3> Data were prospectively...
<h3>Background</h3> In SLE patients, episodes of high disease activity state (HDAS, SLEDAI-2K≥10) are associated with worse outcomes even if only experienced once. We investigated whether attainment the lupus low (LLDAS) was protection against adverse in patients after an episode HDAS. <h3>Objectives</h3> To compare LLDAS between HDAS and non-HDAS patients. <h3>Methods</h3> Data on 4,106 from a multinational cohort, collected prospectively 2013 2020, were analysed. Disease assessed using...
Background Lupus low disease activity state (LLDAS) attainment has been reported to be associated with reduced damage accrual, flare, and mortality, as well improved quality of life, in cohorts SLE patients established disease. Whether these associations are present recent-onset is less known. Objectives To evaluate the LLDAS outcomes recent onset SLE. Methods Data from a 13-country longitudinal cohort (ACR/SLICC criteria) were collected prospectively between 2013 2020 using standard...
<h3>Background</h3> Some studies demonstrated that withdrawal of low-dose glucocorticoids in clinically quiescent systemic lupus erythematosus (SLE) patients increased the risk flare [1]. An international survey 130 clinicians showed persistent abnormal serology led to a reluctance reduce or discontinue medications [2]. <h3>Objectives</h3> To assess and damage accrual after tapering serologically active (SACQ) with SLE. Association other SACQ was also analyzed. <h3>Methods</h3> We used data...
<h3>Background</h3> The lupus low disease activity state (LLDAS) treat-to-target definition sets a ceiling for acceptable and treatment burden in SLE. Definition of Remission SLE (DORIS) is more stringent state, but as it concentric with LLDAS many patients also meet the DORIS remission definition. Studies cohorts majority poorly separate remission, leading to debate about independent effects on outcomes. <h3>Objectives</h3> We examined whether being not provided protection against adverse...
<h3>Background</h3> Systemic lupus erythematosus (SLE) has heterogeneous organ manifestations that occur in different combinations at an individual patient level. Current SLE clinical trial eligibility criteria and efficacy endpoints, based on legacy disease activity measures, have multiple weaknesses. Understanding the frequency with which are represented contemporary cohorts is required, to allow focus most frequent impactful of both endpoints. <h3>Objectives</h3> To report prevalence...